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Abstract: 
Aminorex (5-phenyl-4,5-dihydro-1,3-oxazol-2-amine) and 4-methylaminorex (4-methyl-5-
phenyl-4,5-dihydro-1,3-oxazol-2-amine) are psychostimulants that have long been listed in 
Schedules IV and I of the UN Convention on Psychotropic Substances of 1971. However, a 
range of psychoactive analogs exist that are not internationally controlled and therefore often 
classified as new psychoactive substances (NPS). Aminorex analogs encompass failed 
pharmaceuticals that reemerged as drugs of abuse, and newly synthesized substances that 
were solely designed for recreational use by clandestine chemists. NPS, sometimes also 
referred to as “designer drugs” in alignment with a phenomenon arising in the early 1980s, 
serve as alternatives to controlled drugs. Aminorex and its derivatives interact with 
monoaminergic neurotransmission by interfering with the function of monoamine 
transporters. Hence, these compounds share pharmacological and neurochemical similarities 
with amphetamines and cocaine. The consumption of aminorex, 4-methylaminorex and 4,4’-
dimethylaminorex (4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine) has been 
associated with adverse events including death, bestowing an inglorious fame on aminorex-
derived drugs. In this review, a historical background is presented, as well as an account of 
the pharmacodynamic and pharmacokinetic properties of aminorex and various analogs. Light 
is shed on their misuse as drug adulterants of well-established drugs on the market. This 
review not only provides a detailed overview of an abused substance-class, but also 
emphasizes the darkest aspect of the NPS market, i.e. deleterious side effects that arise from 
the ingestion of certain NPS, as knowledge of the pharmacology, the potency or the identity 
of the active ingredients remains obscure to NPS users. 
 
Keywords: Psychostimulants; designer drugs; new psychoactive substances; aminorex; 
monoamine transporters; drug abuse 
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Introduction 
New psychoactive substances (NPS) are drugs that are not listed in the United Nations 
international drug control conventions of 1961 and 1971 but that may pose comparable threats 
to public health. The NPS term tends to be commonly applied to those substances that have 
emerged in the last decade.1–3 The market is exceedingly dynamic - on a global level, 803 
NPS have been reported to the United Nations Office on Drugs and Crime (UNODC) in the 
period between 2009–2017.4 Within the European Union, the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) is monitoring over 670 substances that have appeared 
over the last two decades5. The drugs encountered on the NPS market are quite diverse in 
nature but include synthetic cannabinoid receptor agonists affecting the endocannabinoid 
system, psychostimulants (largest group), hallucinogens, analgesics, central nervous system 
depressants and others4.  
The psychostimulants aminorex (5-phenyl-4,5-dihydro-1,3-oxazol-2-amine) and 4-
methylaminorex (4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine, 4-MAR) (see Figure 1) 
have been listed (Schedules IV and I, respectively) in the UN Convention on Psychotropic 
Substances of 19716. Aminorex was originally developed as an appetite suppressant with 
marketing authorization in Europe but was then removed from the market in the late 1960s 
due to pronounced adverse effects. In the 1980s, the aminorex analog 4-MAR appeared on the 
drug market and more recently, 4,4′-dimethylaminorex (4-methyl-5-(4-methylphenyl)-4,5-
dihydro-1,3-oxazol-2-amine, 4,4’-DMAR) made its appearance (see below, Figure 1).  
Aminorex and its analogs possess pronounced central nervous system (CNS) effects and, due 
to similarities in their pharmacological profile, might be classified as amphetamine-type 
stimulants. Studying the aminorex family of drugs is worthwhile because it highlights the 
multidisciplinary challenges faced by policymakers, clinicians, law enforcement, users and 
public health professionals.  NPS mimic the effects of controlled drugs (including medicines) 
but are in many cases not controlled at the time when they are released onto the drug 
markets7,8. This has led to large-scale manufacturing of many analogs and derivatives in an 
effort to bypass these controls. As will be detailed below, even some minor changes to 
established structural templates can significantly change the pharmacological profile, which 
can result in severe adverse effects including deaths, thus, requiring the need for in-depth 
research. In addition, the NPS market often lacks control and regulation and consumers are 
prone to being sold mislabeled or heavily adulterated products, which has also been observed 
with aminorex analogs. This family of drugs has been around for over 50 years and even 
though some analogs have been banned, the opportunity for NPS entrepreneurs and organized 
crime groups to explore new analogs and derivatives has never been greater.  
[Fig. 1]  
Historical Context 
Aminorex (Figure 1) was first described by Poos and colleagues in 1963 as one of several 2-
amino-5-aryl-2-oxazolines with anorectic and CNS stimulating properties9. Their employer 
McNeil Laboratories consequently filed a patent claim, detailing various routes of synthesis 
and emphasizing the potent CNS activity of aminorex10. The patent claim also accentuates the 
importance of the introduction of new anorectic drugs to the market as an alternative to the, at 
the time, widely used amphetamine derivatives. To contextualize: From the year 1944 
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onwards, amphetamine derivatives, such as desoxyephedrine (methamphetamine), were used 
in the treatment of obesity in the U.S.A.11 While other amphetamine derivatives were 
developed for the same indication, concerns with respect to their marked cardiovascular side 
effects and dependence-producing properties emerged. Aminorex was considered an 
alternative and, by the name of Menocil and Apiquel, sold over the counter between 1965 and 
1968 in Austria, Germany and Switzerland12,13. Initial results suggested that aminorex 
appeared to be a safe and effective alternative to amphetamine derivatives as anorectic 
medication14. At the same time, Gurtner et al., amongst others, noticed an increase in the 
incidence of patients suffering from pulmonary hypertension in Bern, Switzerland15. In the 
preceding year, Kay and colleagues showed that oral ingestion of a substance can bring about 
the development of pulmonary hypertension in rats16. Soon, the connection was made that the 
ingestion of aminorex was responsible for the five- to twenty-fold increase in patients 
suffering from pulmonary hypertension17–20. The vascular lesions (plexogenic arteriopathy) 
found in patients who died from the ingestion of aminorex were consistent with those 
associated with idiopathic pulmonary arterial hypertension12,21. It was reported that, in Bern, 
20% of those admitted to the hospital due to aminorex intake died at the time, with 50% dying 
in the following ten years18,22,23. Still, in general only between 0.2 and 3% of those who had, 
at the time, ingested aminorex suffered from symptomatic pulmonary arterial 
hypertension19,24–26. A more recent epidemiological study corroborated that the pulmonary 
hypertension epidemic had correctly been attributed to aminorex consumption20. Interestingly, 
the occurrence of pulmonary hypertension, following oral intake of aminorex could not be 
replicated in animal model studies17,27–34. These two observations suggests that individual 
genetic predisposition might have played a major role in the etiology of drug-induced 
pulmonary hypertension19. Current research suggests that the combination of genetic 
predisposition (mainly a mutation in the bone morphogenetic protein receptor type 2; 
BMPR2) and the presence of other risk factors (such as the oral intake of aminorex) increases 
the risk of developing pulmonary arterial hypertension24,35,36. The next steps in the discovery 
relating to mechanisms of action responsible for aminorex-induced pulmonary arterial 
hypertension were soon underway37. Weir and colleagues reported an aminorex-induced 
inhibition of K+ channels in the lung, as well as increased pulmonary artery pressure38,39. 
Nevertheless, most explanations rather emphasize the drug’s interaction with the serotonergic 
system and SERT (serotonin transporter; SLC6A4) in particular40. Seiler and colleagues have 
shown that aminorex causes release of serotonin (5-HT) at SERT, and that it inhibits 5-HT 
uptake, as well as monoamine oxidases41,42. Rothman et al. could confirm aminorex to be a 
substrate of SERT, accumulating intracellularly and causing the efflux of 5-HT43. SERT 
transactivates the platelet-derived growth factor receptor β (PDGFRβ) and SERT, 5-HT and 
5-HT receptors (mostly 5-HT1B) regulate the S100A4/Mts1 gene, inducing c-fos and cyclin 
D1 as well as Rho-kinase expression and activate tyrosine kinases, with each aspect being a 
contributing factor to pulmonary artery smooth muscle cell proliferation35,40,44–47. It is 
therefore likely that the interplay of individual genetic predisposition and oral intake of 
aminorex led to the pulmonary arterial hypertension epidemic, thus, ending the official, over 
the counter sale of aminorex in 196848.  The role of serotonergic mechanisms associated with 
the proliferation in pulmonary arterial hypertension has been reviewed49. 
Although little is known about illicit production and circulation of aminorex during the 1980s, 
it is interesting to note that this drug emerged decades later in a somewhat surreptitious form, 
which sparked new interest in the substance. A little backstory is necessary to understand this 
new development. The anthelmintic drug levamisole is mostly used for veterinary purposes 
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but was originally also intended for use in humans50–52. It is currently still being used for 
treatment in countries where the incidence of helminthiasis in humans is high across the 
population51. New indications, such as the treatment of the steroid-sensitive idiopathic 
nephrotic syndrome, treatment of colorectal cancer, various dermatologic conditions, 
pulmonary tuberculosis, recurrent aphthous stomatitis and severe aplastic anemia, have been 
explored53–58. Illicitly, levamisole is being used as an adulterant in street samples of cocaine. 
This practice has been increasingly reported from the onset of the new millennium onwards 
both in the U.S.A. and Europe59,60. In the beginning, the use of levamisole as an adulterant 
was considered enigmatic59. At the same time, a scandal occurred in the field of horseracing: 
the amphetamine-like drug aminorex was detected in the urine of dozens of horses, 
implicating the owners in illegal doping61. The common denominator in all the alleged doping 
cases was that the horses had been given the anthelmintic drug levamisole beforehand61. 
Barker et al., Bertol et al. and Ho et al. could show that aminorex was indeed formed as a 
metabolite of levamisole in both horses and humans61–63. This explained the detection of 
aminorex in drug screenings following the administration of levamisole, both as a drug and as 
an adulterant of cocaine. Interestingly, Ho et al. also detected the presence of 4-phenyl-4,5-
dihydro-1,3-oxazol-2-amine (rexamino, Figure 1) in horses following subcutaneous 
administration of levamisole63.  
Cocaine is one of the most frequently consumed illicit substances and global cocaine 
production has been increasing during the last couple of years4,64. Common adulterants in 
cocaine include acetaminophen, acetylsalicylic acid, caffeine, lidocaine, (synthetic) 
cathinones, hydroxyzine and levamisole65. The latter is currently the most frequently found 
adulterant, with reports suggesting that between 60% and 80% of all investigated cocaine 
samples are adulterated with levamisole65–69. The abuse of levamisole-adulterated cocaine has 
been thoroughly documented and is associated with influenza-like symptoms, ANCA (anti-
neutrophil cytoplasmic antibody) positive and negative vasculitis, causing retiform purpura, 
and glomerulonephritis, pyoderma gangrenosum, cutaneous necrosis (often of the ears, face 
and/or legs), neutropenia or agranulocytosis, leukocytopenia and multifocal inflammatory 
leukencephalopathy70–105. The media has picked up this story and reports about “flesh-eating 
cocaine” surface from time to time106–108. 
Two major hypotheses, aiming to explain the widespread use of levamisole as an adulterant in 
cocaine, are particularly noteworthy70,109. First of all, levamisole is widely used as a 
prophylactic anthelmintic drug in the livestock industry around the world and prominently so 
in agricultural societies110. Additionally, levamisole is economically highly viable and 
resembles cocaine in melting point, look and taste70. The second hypothesis is centered on the 
effects of cocaine and levamisole although it is unclear whether the decision of drug dealers to 
adulterate the street drug with levamisole deliberately considered its biological fate and its 
overall CNS effect on the user. Cocaine is an inhibitor of monoamine (re)uptake, binding to 
SERT, DAT (dopamine transporter; SLC6A3) and NET (norepinephrine transporter; 
SLC6A2)111. On the other hand, levamisole is a nicotinic acetylcholine receptor agonist, 
which can cause the release of monoamines and inhibits monoamine oxidases and catechol-O-
methyl-transferase112–116. In itself, it is not a very potent inhibitor of monoamine uptake117. It 
appears that the levamisole metabolite aminorex plays an additional role in levamisole-
mediated effects. As discussed later, aminorex is a potent releasing agent at SERT, DAT and 
NET, a quality it shares with amphetamine and many amphetamine-type stimulants117. 
Concerning the biological half-life of levamisole and aminorex, a certain synergism with 
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cocaine is noteworthy. Levamisole and aminorex have a longer half-life than cocaine and can 
therefore prolong the drug experience117–119. Additionally, levamisole has been shown to 
potentiate the rewarding and stimulating effects of cocaine in rats68,109,120. It might be the case 
that the hypotheses are complementary in nature and have both contributed to the fact that 
levamisole is, at this point in time, the most frequently used adulterant in cocaine. One 
question that remains to be answered is the role of the metabolite aminorex in the effects (and 
side-effects) of levamisole-adulterated cocaine. Hess and colleagues have shown in human 
plasma and urine samples collected from drivers (nota bene: under the influence of cocaine) 
that levamisole was present in approximately 40% of the plasma samples. In 10% of the 
samples, aminorex was detected, albeit the concentrations were near the detection limit119. In 
two post mortem urine samples with very high levamisole concentrations, aminorex 
quantification was also significant119. Eiden et al. found levamisole in 75% of all analyzed 
urine samples yet aminorex could not be detected121. In healthy individuals who ingested high 
doses of pure levamisole, comparatively small amounts of aminorex were found in plasma 
and urine118,119. It seems to be the case that the conversion rate from levamisole to aminorex 
might be quite low121,122. Still, Karch et al. describe the case of a deceased long-term poly-
drug user with systemically detectable levamisole and aminorex levels who might have 
suffered from idiopathic pulmonary arterial hypertension and it has been shown that 
levamisole accumulates in lung tissue123–126. Deaths due to levamisole or aminorex toxicity 
associated with the consumption of cocaine have rarely been reported126,127. At this point, it is 
known that only a small fraction of levamisole is metabolized into aminorex and its (side-
)effects seem negligible when compared to those observed with levamisole. Future studies 
should explore the prevalence of pulmonary arterial hypertension in long-term, high-dose 
users of levamisole-adulterated cocaine.  
As mentioned above, there is no evidence of widespread consumption of aminorex in its own 
right, although Brewster and Davis reported in 1991 that aminorex has been, in at least one 
instance, misrepresented as 4-MAR to circumvent legal obstacles128. It appears that aminorex 
is mostly known for its use as an anorectic agent, associated with pulmonary arterial 
hypertension, and as a metabolite of the currently most widely used cocaine adulterant 
levamisole.  
4-MAR (Figure 1) represents another anorectic substance first published by Poos and 
colleagues in 19639. Yet, 4-methylaminorex was never marketed as an anorectic drug11. 
Approximately 25 years later, in the late 1980s, 4-MAR surfaced as a recreational drug and 
was sold by the street names “U4Euh” “ICE” or “4-MAX” in the United States and in 
Europe129. One fatality related to the ingestion of 4-MAR has been reported with the autopsy 
report suggestive of heart and lung failure, including pulmonary and brain edema130. In 
addition, a case study describes three family members, involved in the manufacturing and 
consumption of 4-MAR, who suffered from pulmonary hypertension131. This case report 
suggests that not only aminorex but also its derivative(s) might be appropriate stimuli to cause 
pulmonary hypertension in susceptible individuals. The substance was swiftly added to the list 
of controlled substance in the US and some European countries129. As mentioned above, both 
aminorex and 4-MAR are now controlled internationally and listed in Schedules IV and I of 
the United Nations Convention on Psychotropic Substances 19716.         
Another twenty-five years later, a new aminorex analog appeared on the European drug 
market: 4,4'-DMAR (Figure 1) was introduced to the European NPS market originally offered 
for sale under the brand name “Serotoni”132. The compound was first encountered in 
ACS	Chemical	Neuroscience	(accepted,	uncorrected	version)	
	 6	
December 2012 in a customs seizure in the Netherlands133. Thirty-one deaths occurring 
between June 2013 and February 2014 in Europe were associated with the consumption of 
4,4'-DMAR, with the substance claiming eight victims in Hungary, one in Poland and 22 in 
the United Kingdom133. Clinical notes and autopsy findings reported to the EMCDDA 
revealed hyperthermia, myoclonus, seizures, hallucinations, disorientation, agitation, internal 
bleeding and lung and brain edema, as well as lung and heart failure as the major clinical 
features133. The fatal outcomes were considered consistent with serotonin toxicity and 
norepinephrine-mediated cardiotoxicity133–136. In addition, the combination of 4,4'-DMAR 
with other drugs affecting the monoaminergic system might have contributed to the deaths133. 
4,4'-DMAR tablets mimicked the style of MDMA (1-(2H-1,3-benzodioxol-5-yl)-N-
methylpropan-2-amine, 3,4-methylendioxymethylamphetamine, “ecstasy”/”molly”) tablets 
with respect to colors, shapes and logos133. Unfortunately, 4,4'-DMAR was seemingly 
misrepresented as MDMA and used as an adulterant and/or masking agent to hide the lack of 
the desired drug. It has been shown (see below) that 4,4’-DMAR acted as a 5-10 times more 
potent non-selective monoamine transporter releasing agent compared to MDMA. From this 
perspective, it seems likely that users who thought they had procured ecstasy died from acute 
overdoses as a consequence of norepinephrine, serotonin and dopamine toxicity134,135. These 
tragic events highlight one of the major problems of an unregulated, illicit NPS market – the 
misrepresentation of substances and the addition of under-researched adulterants that can lead 
to adverse effects including fatalities.  
The identification of 4,4’-DMAR and its association with deaths occurring between June 2013 
and February 2014 in Europe led to swift responses. In Europe, the EMCDDA launched a 
Joint Report to assess the available information in early 2014 followed by a risk assessment 
carried out by the EMCDDA’s Scientific Committee in September 2014133,137. Upon 
reviewing the available information, a decision was made by the European Council to subject 
4,4’-DMAR to Europe-wide control measures in 2015138. At a global level, and under the 
auspices of the World Health Organization, 4,4’-DMAR (amongst other substances) 
underwent the critical review stage at the thirty-seventh meeting of the Expert Committee on 
Drug Dependence in November 2015139. It was recommended to place 4,4’-DMAR in 
Schedule II of the UN 1971 Convention, which was subsequently confirmed by vote by the 
Commission on Narcotic Drugs in 18 March 2016, thus, placing it under international 
control140,141. Interestingly, 4,4’-DMAR still appears to be available for purchase from online 
vendors, mostly based in Chinae.g.142, although it is unclear whether these vendors are able to 
supply it. In an Internet snapshot study published in 2014, it was reported that 4-MAR was 
advertised more frequently than 4,4'-DMAR143.  
The 4,4’-DMAR case demonstrated that the NPS market can employ mechanisms of self-
correction and that when a substance is noticed to be dangerous, some Internet retailers 
abstain from selling this substance and shift their focus to other compounds. At the same time, 
the fact that 4,4’-DMAR was surreptitiously sold in mislabeled forms suggests the potential 
involvement of organized crime groups that sell NPS on the traditional illicit market as well. 
However, the discussions surrounding 4,4’-DMAR on user fora remains active to some 
extent.144 Users seem to be hesitant to consume 4,4'-DMAR because of its association with 
the fatal intoxication cases but younger users who missed the opportunity to consume 4-MAR 
when it was uncontrolled in the 1980s, appear to express interest in a revival145–147. NPS users 
and clandestine chemists turn to various new substituents and derivatives of aminorex with 
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the hope to conserve the desired effects while simultaneously decreasing side-effects and 
toxicity (see Structural Features). 
 
 
 
Structural Features  
Aminorex and its derivatives are amphetamine-type (1-phenylpropan-2-amine) stimulants that 
contain one amino-oxazoline (4,5-dihydro-1,3-oxazol-2-amine) and one phenyl ring (Figure 
1). One methyl group is added to the amino-oxazoline ring for 4-MAR (2-amino-4-methyl-5-
phenyl-2-oxazoline) and MDMAR (5-(2H-1,3-benzodioxol-5-yl)-4-methyl-4,5-dihydro-1,3-
oxazol-2-amine, Figure 1). Additionally, for 4,4ʹ-DMAR (4-methyl-5-(4-methylphenyl)-4,5-
dihydro-1,3-oxazol-2-amine), the phenyl ring is also methylated. Structurally, MDMAR 
constitutes an interesting MDMA and 4-MAR hybrid, containing the characteristic 1,3-
dioxolane ring.148 
Aminorex contains one chiral carbon and the available information indicates that it has only 
been evaluated as a racemic mixture. 4-MAR and other closely related analogs, for example 
disubstituted at C4 and C5, give rise to four stereoisomers, namely trans-(4R,5R), trans-
(4S,5S), cis-(4S,5R) and cis-(4R,5S), and/or to two racemates, (±)-trans and (±)-cis forms. 
Marked differences in activity and potency between cis- and trans isomers have been reported 
for some of these compounds.134,148–154 (see Pharmacodynamics & Pharmacokinetics). It has 
been shown for many amphetamine-type stimulants that isomers with an (S)-configured α-
methyl group are more potent pharmacodynamically than the (R)-isomers155–157.   
The 4,4ʹ-DMAR isomer 3,4-dimethylaminorex (3,4-MAR, Figure 1) has been considered 
structurally similar to methamphetamine155. It has first been described by Poos and 
colleagues9. The analog seems to be a compound that has rarely been reported as a street drug 
but has rather been experimented with in scientific laboratories153,155,158. However, similar to 
N-methylaminorex (Figure 1), it has been detected in the European Union in 2015159. Various 
other, seemingly lesser known derivatives of aminorex have been mentioned in publications 
or the Internet but have not been investigated in a systematic manner160. Poos et al. have 
characterized various other locations (on the phenyl and oxazoline ring) and substituents and 
an overview of aminorex analogs has been published by Trachsel et al.9,161 (Figure 2).  
[Fig. 2] 
Since the discovery of 4-MAR on the street market in the 1980s it is not surprising that this 
has caught the attention of law enforcement officials. In a reflective piece on future drugs of 
abuse published by Cooper as part of an international symposium held in 1988, the author 
lists aminorex, 4-MAR and six other analogs of particular interest (anorectic potency in rats 
comparable to amphetamine) (Figure 2) that were based on the work on Poos and colleagues 
from McNeil Laboratories9. Although not specifically mentioned in this personal 
communication between Poos and Cooper, the author also suspected the 4-fluoro- and 4-
chlorophenyl analogs of 4-MAR and N,N-dimethyl-4-MAR to have “psychotomimetic” 
properties10,162,163. Other examples disclosed in a patent published by Poos included 4-alkyl 
analogs of aminorex (Figure 3) and methoxyphenyl-substituted analogs, although detailed 
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information was not provided10. Information about their occurrence on the streets is currently 
unavailable.  
[Fig. 3] 
Similarly, the literature based on the work carried out at McNeil Laboratories sparked interest 
among individuals interested in the chemistry and psychopharmacological exploration of 
psychoactive substances, collectively interacting through an online discussion forum called 
The Hive that was in operation between 1997–2004. Many of the posts are still available in 
archived form online164. The idea of preparing 4,4′-DMAR following established aminorex-
type chemistry was proposed in 2003 (the idea apparently emerged during the synthesis of 4-
methylmethcathinone that several years later became known as the NPS mephedrone), 
although it is unclear whether this was taken further by any other Hive member165. 
More recently, a user of another online drug forum shared information on a method of 
synthesis and effects related to 5-(2-fluorophenyl)-4,5-dihydro-1,3-oxazol-2-amine, i.e. the 
ortho-fluoro analog of 4-MAR (Figure 3)166,167. It was stated that the fluorinated analog was 
believed to be safer and less cardiotoxic,166 which illustrates the persistent interest of the NPS 
community in aminorex derivatives while expressing a cautious approach toward minimizing 
possible side-effects and toxicity. Still, there seems to be a scientific basis for such an 
assumption because Rickli and colleagues have shown that 4-methyl and 4-bromo 
substitutions lead to more potent serotonergic properties than 4-fluoro groups168. It appears 
that users expressed an interest in the fluoro-substituted analog169 and it was also mentioned 
that it might be already available for purchase170. A recent report from an online test purchase 
conducted by the Slovenian National Forensic Laboratory, suggests that the para-fluoro 
analog of 4-MAR (5-(4-fluorophenyl)-4-methyl-4,5-dihydro-1,3-oxazol-2-amine, 4’F,4-
MAR) is also available for purchase from Internet vendors171 (Figure 1). This substance has 
been offered for sale under the label “4-FPO” and mostly consists of the trans-isomer171. The 
mislabeled substance is currently being discussed in various user fora and sometimes 
described as a phenmetrazine derivative, which highlights the potential for confusion172–175. 
Its synthesis has even been described in detail by a clandestine chemist176. These new 
developments illustrate the abiding relevance of and interest in aminorex and its analogs in 
the NPS scene.   
Synthesis 
The procedure reported by Poos and co-workers for the preparation of 4-MAR analogs 
involved the reaction of 2-amino-1-phenylpropan-1-ol precursors with cyanogen bromide 
followed by cyclization. Correspondingly, the use of 2-amino-1-phenylethanol has been 
described to provide aminorex9. Furthermore, Poos et al.9 and Klein et al.129 showed that the 
reaction of cyanogen bromide with the norephedrine led to the formation of the cis-racemate 
whereas the employment of norpseudoephedrine gave the trans-form of 4-MAR. 
Interestingly, when investigating a case related to the clandestine synthesis of 4-MAR, it was 
found that norephedrine could be converted predominantly to the trans-product by reaction 
with potassium cyanate177, an idea that has been discussed on The Hive forum178. The recent 
characterization of a 4’F-4-MAR sample obtained from a test purchase revealed the presence 
of the trans-form and the detection of the cis-form as a minor component171. In analogy to 
what has been described during the forensic investigation of the trans-4-MAR synthesis177, it 
would be interesting to consider that the conversion of the 2-amino-1-(4-fluorophenyl)propan-
1-ol precursor might have involved potassium cyanate as well. Interestingly, the procedure 
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described for the synthesis of 4’F-4-MAR on the Internet also involved the use of this same 
reagent although the described procedure did not reveal whether the resulting aminorex 
analog represented the trans- or cis-form176. The synthesis of racemic cis- and trans-4,4’-
DMAR is shown in Figure 4, which was based on the reaction of 2-amino-1-(4-
methylphenyl)propan-1-ol with either cyanogen bromide or potassium cyanate. 1-(4-
Methylphenyl)propan-1-one served as the starting material for the preparation of the alcohol 
intermediate (Figure 4)134. Correspondingly, cis- and trans-MDMAR have been prepared via 
the norepinephrine-type precursor 2-amino-1-(2H-1,3-benzodioxol-5-yl)propan-1-ol148. An 
interesting observation reported for MDMAR (and not for 4,4’-DMAR) was that the racemic 
cis-form converted to the trans-form when exposed to water-containing solutions but not 
when exposed to acetonitrile, which suggested a potential role of water in this conversion 
process148.  
[Fig. 4]       
Pharmacodynamics & Mechanisms of Action  
It was known to Poos and colleagues that aminorex was not only an anorectic drug but also a 
drug with CNS stimulating properties9. Another study from the same laboratory revealed that 
aminorex was a releasing agent of catecholamines179. Rothman and colleagues later confirmed 
that aminorex was not a mere non-transported uptake inhibitor of monoamine transporters 
(like cocaine) but rather a releasing agent similar to amphetamine and that its main effects 
derived from its interaction with the monoamine transporters NET, DAT and SERT180. Since 
then, various groups have also performed transporter release assays, classifying aminorex and 
its derivatives as monoamine transporter substrates and releasing agents of 
monoamines134,135,148.   
Brandt et al. and McLaughlin and colleagues have demonstrated that aminorex, 4-MAR, 4,4'-
DMAR and MDMAR were potent releasing agents in rat brain synaptosomal preparations at 
DAT, SERT and NET, with the lowest EC50 (half maximal effective concentration) at DAT, 
followed closely by NET and SERT134,148 (see Table 1). Furthermore, it has been shown that 
the presence of additional methyl groups added onto aminorex to form 4-MAR and 4,4'-
DMAR have barely changed its potency to cause efflux of monoamines at DAT and NET but 
have immensely increased its releasing potency at SERT134. The DAT/SERT ratio, with 
higher values indicating greater selectivity for DAT over SERT, was 45 for aminorex, 31 for 
4-MAR and only 2 for 4,4'-DMAR134. In closely related substances, it has been established 
that substitution of the para-position led to decreased selectivity for DAT over SERT168,181,182. 
In comparison, MDMA’s DAT/SERT ratio is 0.6 but its EC50 was five to ten times higher 
than that reported for 4,4'-DMAR148. MDMAR’s potency was slightly lower than that of 4,4'-
DMAR but higher than MDMA’s148.         
It has recently been shown that 4,4'-DMAR binds to monoamine transporters with higher 
affinities compared to monoamine receptors, albeit it has also been shown to bind to hDAT, 
hNET, hSERT and 5-HT2A and 5-HT2C receptors with relatively low affinities135 (see Table 
1). Due to the lack of interaction with the trace amine-associated receptor 1 (TAAR1), 4,4'-
DMAR is suspected to be unable to trigger the auto-inhibitory pathway that, for example, 
MDMA possesses at least in rodents135,183,184. 
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Aminorex 
DAT NET SERT Reference Cell system 
Inhibition 
IC50 in 
nM 
Release 
EC50 in 
nM 
Affinity 
Ki in nM 
Inhibition 
IC50 in nM 
Release 
EC50 in 
nM 
Affinity 
Ki in nM 
Inhibition 
IC50 in 
nM 
Release 
EC50 in 
nM 
Affinity 
Ki in nM 
  
-- 9.1±0.9 -- -- 15.1±3.5 -- -- 414±78 -- Brandt et 
al.134 
Rat brain 
synaptosomes 
710±1050 -- -- 1970±1200 -- -- 26,290 
±1,030 
-- -- Hofmaier et 
al.117  
HEK293 
cells 
[Ki = 
216±7] 
-- 784±16 -- -- -- [Ki = 
1,244±106] 
-- 27,700±990 Rothman et 
al.43  
Rat brain 
synaptosomes 
[Ki = 
216±7] 
49.4±7.5 -- [Ki = 
54.5±4.8] 
26.4±2.8 -- [Ki = 
1,244±106] 
193±23 -- Rothman et 
al.111,180,185,186  
Rat brain 
synaptosomes 
-- -- -- -- -- -- [Ki = 
1,380] 
[% above 
basal 
flow: 51-
116] 
-- Tao et al.187  Rat brain 
tissue 
4-methylaminorex 
-- 1.7±0.2 -- -- 4.8±0.9 -- -- 53.2±6.8 -- Brandt et 
al.134  
Rat brain 
synaptosomes 
((±)-cis-4-
MAR) 
4,4’-dimethylaminorex 
-- 8.6±1.1 -- -- 26.9±5.9 -- -- 18.5±2.8 -- Brandt et 
al.134  
Rat brain 
synaptosomes 
((±)-cis-4,4’-
DMAR) 
1040 
(95% CI: 
848 to 
1282) 
-- 533.8±44.2 500 (95% 
CI: 
447 to 
553) 
-- 266.8±57 1750 (95% 
CI: 1446 to 
2126) 
-- 1881±183.1 Maier et 
al.135  
HEK293 
cells 
((±)-cis-4,4’-
DMAR) 
-- 10.9±0.7 -- -- 11.8±2.0 -- -- 17.7±2.3 -- McLaughlin Rat brain 
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et al.148  synaptosomes 
((±)-cis-4,4’-
DMAR) 
-- 24.4±2.7 -- -- 31.6±4.6 -- -- 59.9±17.2 -- McLaughlin 
et al.148 
Rat brain 
synaptosomes 
((±)-trans-
4,4’-DMAR) 
 
Table 1: In vitro uptake inhibition, release and affinity data for aminorex and its analogs.   
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Poos and colleagues could not notice differences in potency between cis and trans-4-MAR as 
far as the ability to reduce food intake in rats was concerned9. As previously mentioned, 
amphetamine-type stimulants that possess an (S)-configured α-methyl group are generally 
more potent in producing effects in the central nervous system than the respective (R)-
isomers188. Correspondingly, it has been shown for 4-MAR that trans-(4S,5S) is more potent 
than cis-(4S,5R) and cis-(4R,5S) at increasing extracellular dopamine concentrations and thus 
causing dopamine-related, dose-dependent locomotor activation 149,150,152 (see Table 2). 
Concerning the compounds’ 5-HT release, it has been shown that cis-(4S,5R) is more potent 
than trans-(4S,5S) and cis-(4R,5S)149. Glennon and Misenheimer have shown that the trans-
(4S,5S) isomer is the most potent isomer at the generalization of (S)-(+)-amphetamine stimuli, 
followed by the two cis-isomers151. All these studies showed the trans-(4R,5R) isomer have 
the, by far, weakest potency. Whether a direct relationship between the substance’s potency 
and its number of (S)-configured methyl groups exists, similar to (S)-amphetamine, remains to 
be established. While it has been shown for 4-MAR that the (±)-trans racemate is more potent 
than the (±)-cis racemate to induce stimulus generalization in rats, a study comparing the 
potency of 4,4'-DMAR and MDMAR racemates in rat brain synaptosomes paints a different 
picture148,151 (see Table 2). McLaughlin and colleagues point out that the (±)-cis racemates of 
4,4'-DMAR and MDMAR seem to be slightly more potent than the respective (±)-trans 
racemates at evoking efflux at monoamine transporters148. 
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Aminorex 
Model organism Results Study 
Humans Toxic doses for humans were determined to be located between 1-2 
mg/kg. Symptoms occur between 15 and 120 mins after consumption 
and are characterised by seizures, respiratory depression, mydriasis, 
tachycardia, hypertension and hyperpnea.  
Borbély et al.189 
Hereford calves An increase in arterial blood pressure but no pulmonary side-effects 
after daily i.v. injections (0.25 mg/kg) for one month were reported. 
Byrne-Quinn & 
Grover28 
Sprague-Dawley rats A dose of 1.5 µmol/kg, administered i.v., elicited increased motor 
activity. Stereotypical behaviour was not detected in doses up to 112 
µmol/kg.  
Costa et al.37  
Wistar rats After administration of 6.5 to 22mg/kg aminorex daily for 118 
consecutive days, no anatomical differences of the pulmonary vessels 
were detectable. 
Engelhardt & Hort32 
Humans This retrospective study highlighted that anticoagulant therapy with 
warfarin in aminorex-caused pulmonary hypertension had beneficial 
effects on their survival time.  
Frank et al.190 
Rabbits  Aminorex was found to be an efficient 5-HT releaser in platelets, 
similar in potency to amphetamine.  
Friström et al.191 
Human subjects Two studies (79 and 60 subjects) have proven aminorex (7.5 mg) to be 
an effective anorectic agent, similar to dextroamphetamine and 
diethylpropion but more effective than phenmetrazine. Side-effects 
concerning the CNS, the GI tract and the renal system, as well as 
leukopenia were reported.  
Hadler14 
Mongrel cats 1.0 mg/kg i.p. caused a 90 % decrease in food intake and lead to 81.5 
% of a 12 hour session being spent awake, 16.5 % in slow-wave sleep 
and 2.0 % in paradoxical sleep.  
Johnson et al.192 
Baboons Self-injection experiments showed for doses of 0.1 and 0.32 
mg/kg/injection cyclical patterns of self-injection, with numbers of 
injections per day similar to cocaine, suggesting abuse potential. Food 
intake was decreased significantly at the highest concentration.  
Kaminski et al.193 
Wistar albino rats; beagle dogs Treatment with aminorex for 43 (rats) and 20 weeks (dogs) did not Kay et al.17 
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reveal evidence of pulmonary vascular disease. 
Human subjects Aminorex was shown to be an effective anorectic drug and no relevant 
side-effects were reported after a daily intake of 10 mg for 120 days 
(20 patients). 
Kew194 
Beagle dogs Treatment of dogs with high doses of aminorex for 13 weeks led to no 
significant pulmonary and cardiac abnormalities.  
Leuschner et al.33 
Swine (young) Aminorex was given for three months but no significant cardiovascular 
and pulmonary side-effects could be detected.  
Mlczoch et al.195 
Swine Up to 15 mg/kg of aminorex per day was fed to swine for four months. 
No signs of pulmonary arterial hypertension could be detected but a 
slight decrease in cardiac and pulmonary function was noticeable.  
Orr et al.31 
Sprague-Dawley rats Aminorex was shown to be amongst the most potent amphetamine-
type stimulants concerning its ability to evoke anorexia and stimulant 
activity.  
Paul et al.196 
CHO cells Aminorex inhibits hKv1.5 channels with a KD > 300 µM. Perchenet et al.39 
Rats Aminorex was shown to have an ED50 of 5.8 mg/kg. Poos et al.9  
Rats 3 and 6 mg/kg were administered orally and motor activity was 
evaluated. Aminorex, when compared to 4-MAR and amphetamine, 
was shown to reach peak motor activity levels earlier (after 40 minutes) 
than the other compounds (4-MAR after 80 minutes and amphetamine 
after 130 minutes).  
Poos et al.197 
Sprague-Dawley rats Aminorex was shown to generalise for amphetamine and to have an 
ED50 of 3.0 µmol/kg. No stimulus generalisation could be obtained 
with rexamino. 
Russell et al.153 
Wistar rats Aminorex induced stereotyped behaviour, lasting three hours at 5.0 
mg/kg, administered s.c. in rats pre-treated with α-methyl-p-tyrosine. 
Sayers & Handley198 
Patas monkeys Up to 4 mg/kg of aminorex was administered for 347 consecutive days 
and cardiac catheterization and autopsy results revealed no significant 
pulmonal and cardiac pathologies.  
Smith et al.29  
Mongrel dogs Administration of 1.0 to 1.5 mg/kg aminorex five times per week over 
two years lead to histologically detectable changes in the pulmonary 
arteries of 60% of the dogs. The changes were not as severe as those 
Stepanek & Zak34 
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detected in humans suffering from pulmonary arterial hypertension.  
Chinese hamsters, V79 Chinese hamster 
cells, Saccharomyces cerevisiae, 
Escherichia coli, Salmonella typhimurium 
In contrast to other amino-oxazoline derivatives, mutagenic effects of 
aminorex could not be shown in vitro and vivo. Most of the other 
tested compounds were mutagenic but methylation of the oxazoline 
ring reduced the detrimental effects.  
Suter et al.199 
Sprague-Dawley rats Aminorex caused 5-HT release in rat hypothalamus in a dose-
dependent manner. 
Tao et al.187 
Beagle dogs 1.5 mg/kg aminorex was orally administered and transient increases of 
pulmonary and systemic arterial blood pressure but no formation of 
pulmonary hypertension were noted. 
Will & Bisgard30  
Rhesus monkeys, CF-1 mice, Sprague-
Dawley rats 
Aminorex substituted for amphetamine in generalisation tests, served 
as a positive enforcer (both in monkeys), caused stimulant-mediated 
locomotor effects at 1.25 mg/kg (mice) and worsened signs of 
withdrawal (rats).  
Woolverton et al.200 
Sprague-Dawley rats Stimulus-generalisation tests revealed that aminorex is recognised by 
rats as an amphetamine-type stimulant (starting from doses of 0.5 
mg/kg).  
Young201 
Sprague-Dawley rats 4-MAR (ED50=1.11) was six times less potent than aminorex 
(ED50=0.22) in cocaine stimulus generalisation experiments.  
Young & Glennon202 
Sprague-Dawley rats Aminorex (1 µmol/kg) substituted for S-methcathinone in stimulus 
generalisation experiments with an ED50 of 0.27 mg/kg.  
Young & Glennon203 
CBA mice Between 25 mg/kg were injected intraperitoneally for three times in 24 
hours. No significant changes in DOPAC or 5-HIAA, as well as no 
long-lasting depletion of monoamines could be detected. 
Zheng et al.155 
4-methylaminorex 
Sprague-Dawley rats The trans-4S,5S-isomer was the most potent isomer concerning a 
suppression of the basal firing rate of spontaneously active 
dopaminergic neurons (trans-4S,5S > cis-4R,5S = cis-4S,5R >>trans-
4R,5R). This effect could be reversed by the addition of haloperidol 
and the D2 and D3 receptor antagonists eticlopride and sulpiride. The 
(pre-)treatment with pindolol, fluoxetine, granisetron and phentolamine 
(amongst others) did not change the effects, while pre-treatment with 
Ashby et al.150 
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α-methyl-p-tyrosine and reserpine did.    
Sprague-Dawley rats The isomers of 4-MAR were ranked according to their ability to induce 
stereotyped behaviour at various doses: trans-4S,5S > cis-4R,5S = cis-
4S,5R >trans-4R,5R. This effect could be attenuated by administration 
of dopamine receptor antagonists, suggesting a dopaminergic neural 
causation of 4-MAR’s behavioural effects. 
Batsche et al.152 
Humans A case is described where aminorex was misrepresented as 4-MAR. Brewster & Davis128 
Sprague-Dawley rats Acute changes after administration of a single dose were determined. 
Between 5 and 20 mg/kg were administered. Tryptophan hydroxylase 
activity declined in a dose-dependent manner. Locomotor activity was 
dose-dependent and 20 mg/kg led to clonic seizures, oftentimes fatal.     
Bunker et al.204 
Humans A fatality involving 4-MAR is described (blood levels: 21.3 mg/L and 
urine levels: 12.3 mg/L). 
Davis & Brewster130 
Humans A case study is presented where three members of a family that 
produced and consumed 4-MAR, developed pulmonary hypertension. 
Gaine et al.131 
Sprague-Dawley rats Administration of the cis- and trans-racemate led to amphetamine 
stimulus generalisation with the trans-racemate being three times more 
potent than the cis-racemate (ED50: trans-4S,5S, 0.25 mg/kg > cis-
4S,5R, 1.22 mg/kg = cis-4R,5S, 1.52 mg/kg > trans-4R,5R). 
Glennon & 
Misenheimer151 
CF-1 mice The seizure-causing properties of 4-MAR were evaluated. Its CD50 was 
determined to be 90µg and its CD97 110 µg, following 
intracerebroventricular injection. Thus, 4-MAR has a very steep dose-
seizure curve.  Onset of the seizures was intermediate (between 60-300 
sec) and clonus duration was between 30 and 300 sec. After the 
termination of clonic activity, a second seizure episode followed after a 
short period of behavioural arrest. Flunarizine and valproate could be 
shown to be effective in preventing 4-MAR-caused seizures.  
Hanson et al.205 
Wistar rats The rank order of potency for elevating extracellular dopamine levels 
was trans-4S,5S > cis-4S,5R = cis-4R,5S >trans-4R,5R 4-MAR and for 
elevating 5-HT cis-4S,5R >trans-4S,5S = cis-4R,5S > trans-4R,5R. All 
isomers caused a decrease of extracellular concentrations of DOPAC 
and HVA. At lower doses (2.5 and 5.0 mg/kg), the isomers (except for 
Kankaanpää et al.149 
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trans-4R,5R) caused rises in locomotor activity and high doses (10 
mg/kg) caused biphasic behaviour patterns, with initial rises in 
locomotor activity being followed by rapid declines and engagement in 
stereotyped behaviour, ataxia or catatonia. 
Baboons, rhesus monkeys Self-administration experiments highlighted cyclical patterns of self-
injection, where days with many injections (0.32 mg/kg/injection) were 
followed by low-rate days (in baboons). This behaviour lead to 
agitation, stereotypic movements, hypersensitivity and hallucinations. 
Rhesus monkeys had unlimited access to the compound for one hour 
and administered up to 100 injections (0.003 to 0.03 mg/kg/injection). 
The results were interpreted as 4-MAR having strong potential for 
abuse. 
Mansbach et al.206 
Wistar rats Conditioned place preference tests revealed that all isomers 
equipotently induced preference. This effect was, for some isomers, 
attenuated by the administration of dopamine receptor antagonists and 
lesions in the nucleus accumbens. Rewarding properties of 4-MAR 
consumption were revealed to be connected to the dopaminergic 
system.    
Meririnne et al.207 
Rats The ED50 of cis-4-MAR was determined to be 8.8 mg/kg.  Poos et al.9  
Rats 3 and 6 mg/kg were administered orally and motor activity was 
evaluated. 4-MAR caused peak motor activity levels earlier (after 80 
minutes) than amphetamine (130 minutes) but later than aminorex (40 
minutes).   
Poos et al.197 
Sprague-Dawley rats 4S,5S-4-MAR was shown to generalise for amphetamine and to have 
an ED50 of 1.7 µmol/kg.  
Russell et al.153 
Mongrel dogs Sympathomimetic effects of the compound can be attributed to an 
increased release of catecholamines (published in 1963). 
Yelnosky & Katz179 
Sprague-Dawley rats 4-MAR (ED50=1.11) was six times less potent than aminorex 
(ED50=0.22) in cocaine stimulus generalisation experiments.  
Young & Glennon202 
Sprague-Dawley rats Cis-4-MAR (2.3 µmol/kg) substituted for S-methcathinone in stimulus 
generalisation experiments with an ED50 of 0.49 mg/kg.  
Young & Glennon203 
CBA mice Between 5 and 30 mg/kg (depending on the stereoisomer) were Zheng et al.155 
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injected intraperitoneally for three times in 24 hours. DOPAC levels 
were increased but no long-lasting depletion of monoamines could be 
detected. 
4,4’-dimethylaminorex 
Sprague-Dawley rats  An extensive chemical analysis of 4,4'-DMAR was conducted (crystal 
structure analysis, mass spectrometry, chromatography and 
spectroscopy). Monoamine transporter assay results are mentioned in 
Table 1. 
Brandt et al.134 
-- A mini-review of 4,4'-DMAR. Coppola & Mondola208 
Humans 4,4'-DMAR-caused fatalities were examined. Post-mortem 
concentrations of 4,4'-DMAR were between 0.20 to 3.75 mg/L. Liquid 
chromatography and mass spectrometry approaches of screening for 
4,4'-DMAR were described. 
Cosbey et al.209 
-- A mini-review of 4,4'-DMAR. Glanville et al.210 
-- Drug fora were analysed to paint a picture of the way users discussed 
4,4'-DMAR. 
Loi et al.144 
HEK293 cells, rPC12 cells, human striatal 
synaptic vesicles 
4,4'-DMAR was classified as a non-selective monoamine releasing 
agent and binding data was provided. Inhibition of VMAT2 hints at 
long-term neurotoxic effects in chronic abusers of the substance.  
Maier et al.135 
Sprague-Dawley rats An in-depth chemical analysis of MDMAR was provided. In addition, 
monoamine transporter assays comparing cis-MDMAR, trans-
MDMAR, cis-4,4′-DMAR and trans-4,4′-DMAR are portrayed in 
Table 1. 
McLaughlin et al.148 
-- An internet snapshot survey was conducted to analyse the availability 
of 4,4'-DMAR and 4-MAR in April 2014. 
Nizar et al.143 
Table 2:  A summary of pharmacodynamic and toxicological studies on aminorex and its analogs.  
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Pharmacokinetics  
Aminorex, when available as an anorectic drug, existed in the form of 7.5 to 20 mg aminorex 
fumarate, base or pamoate tablets, to be consumed orally211. 4-MAR seems to mostly have 
been ingested orally, insufflated or smoked in doses ranging from 5 to >25 mg depending on 
the routes of administration212. 4,4'-DMAR has mostly been consumed orally or insufflated 
but has also been inhaled and administered i.v. with doses ranging from 10 to 200 
milligrams133,208,210. 
Cressman and colleagues have tested the change of aminorex fumarate plasma concentration 
over time in human participants.211 They have shown that aminorex fumarate has a relatively 
long half-life of 8 hours and effects can even be prolonged and high concentrations 
maintained by utilizing sustained-release tablets. It has been determined in horses that 
aminorex is rapidly absorbed (with a half-life of 30 minutes) and that it is eliminated in 
various steps with a half-life of 24 hours in the slow, extended terminal elimination phase213. 
This can be pharmacokinetically modelled via a multi-compartment model where the 
compound is quickly eliminated from plasma and accumulates in deeper compartments and is 
then slowly metabolized (see Table 3). The accumulation of aminorex and its derivatives 
might explain the reported cyclical patterns of 4-MAR self-administration in baboons with 
high rate of self-injection across days alternating with low rates across days206. For (±)-cis-
4,4'-DMAR, Lucchetti and colleagues have shown that the compound is rapidly distributed 
into peripheral tissue, easily passes the blood-brain-barrier and is slowly eliminated with a 
half-life of five hours214. The compound has been shown to be lipophilic with a brain-to-
plasma ratio three times that of (±)-cis-4-MAR154,215.  
Concerning the metabolic fate of aminorex, unpublished data from McNeil Laboratories 
seems to suggest that 31% are excreted non-metabolized and that the amino-oxazoline ring is 
being hydrolysed to hydroxyphenylurea216. Previously, another study identified 
hydroxyaminorex as one major metabolite in horses213. Henderson and colleagues have found 
three metabolites of 4-MAR: (i) the active metabolite norephedrine, caused by the hydrolysis 
of 4-MAR; (ii) 4-(2-amino-4-methyl-4,5-dihydro-1,3-oxazol-5-yl)phenol, emerging through 
hydroxylation; and (iii) 4-methyl-5-phenyl-1,3-oxazolidin-2-one, caused by the deamination 
of 4-MAR216. It was also hypothesized that the methyl group might inhibit the hydrolysis of 
the amino-oxazoline ring. Lucchetti and colleagues could produce similar results for (±)-cis-
4,4'-DMAR215. They discovered four metabolites, caused by hydrolysis, hydroxylation, 
deamination (which has already been shown for 4-MAR) and oxidation of the compound. The 
main metabolite located in plasma and brain was the one not detected in 4-MAR, caused by 
oxidation of 4,4'-DMAR’s para-methyl group215. It has been demonstrated that aminorex is 
mostly eliminated renally over the course of 72 hours211. 
It has been revealed that the concentration of the two trans isomers of 4-MAR in rat brain 
tissue, 30 minutes after i.p. injection, is significantly higher than that of the cis isomers217. 
Similarly, the concentration of trans isomers is also increased in dialysate and plasma149. 
Additionally, the elimination of the trans-(4R,5R) isomer is three times slower than that of the 
others154. The bioavailability of the trans-(4R,5R) isomer is significantly higher than the other 
isomers’, indicating protection from pre-systemic metabolic degradation. It has been shown to 
accumulate in tissue, i.e. mostly in the kidney, liver, brain and muscles, significantly more 
than the other isomers of 4-MAR. There is a remarkable difference in pharmacokinetic 
properties between trans-(4S,5S)-, cis-(4S,5R)- and cis-(4R,5S)-isomers, which resemble 
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each other, and the trans-(4R,5R) isomer. It is remarkable that, even though the brain 
concentration of trans-(4R,5R)-4-MAR is by far the highest, the substance is less potent than 
the other isomers154.   
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Aminorex 
Model organism ADME Results Study 
In vivo: human subjects; in 
vitro dissolution 
A Aminorex fumarate, as sustained-release tablets in 
doses of 15 and 20 mg/tablet, was determined to have 
good absorption rates and allow for prolonged effects. 
Cressman et al.211 
In vivo: Standardbred gelding 
horses; in vitro: horse liver 
microsomes 
M Aminorex and rexamino were discovered to be 
metabolites of levamisole in horse urine and plasma. 
Ho et al.63 
In vivo: Thoroughbred horses A, D, E Aminorex was administered orally and i.v. Distribution 
could be described by a three-compartment (with half-
lives of 0.04, 2.30 and 18.82 hours) and a two-
compartment model, respectively. The substance was 
renally eliminated and urinary excretion peaked after 
two hours for the i.v. group and six hours for the p.o. 
group.  
Soma et al.213  
4-methylaminorex 
In vivo: Sprague-Dawley rats M, E 4-MAR is mostly eliminated renally (and secondly via 
the GIT) in its unchanged form (60%). Three 
metabolites could be identified: 4-MAR is hydrolysed 
to norephedrine, the phenyl ring can be hydroxylated to 
form 2-amino-5-[p-hydroxyphenyl]-4-methyl-2-
oxazoline and deamination leads to metabolite 5-
phenyl-4-methyl-2-oxazolidinone.  
Henderson et al.216 
In vivo: Wistar rats E 4-MAR isomers could be detected by more than half of 
the tested on-site immunoassays, mostly as (meth-
)amphetamine or cocaine. How to detect and quantify 
4-MAR in urine using TLC and GC/MS is described in 
detail. 
Kankaanpää et al.217 
In vitro A Chemical properties of the stereoisomers are described 
in detail. 
Klein et al.129 
In vivo: Wistar rats A, D, M, E Oral bioavailability of 4-MAR was significantly lower 
than after i.v. or intraperitoneal administration.  
Meririnne et al.154 
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Marked differences between the isomers concerning 
their half-lives were found (for details see main text). 
Elimination of the trans-4R,5R-isomer was 3 times 
slower than that of the others. 
The highest concentrations of 4-MAR were located in 
the kidney, liver, brain and muscles, suggesting a 
significant ability to cross the blood-brain-barrier.  
The metabolites norephedrine (from the cis-isomers) 
and norpseudoephedrine (from the trans-isomers) were 
detected in blood and brain.   
4,4’-dimethylaminorex 
In vivo: Wistar rats  A, D, E 1 mg/kg cis-4,4′-DMAR was given i.v. The compound 
was more rapidly and extensively distributed than 4-
MAR and more slowly eliminated (plasma t1/2 of 5.14 ± 
0.65 h). I.p. doses of cis-4,4′-DMAR (1, 3 and 10 
mg/kg) show a dose-dependent AUC. Data was 
quantified with HPLC-MS/MS.  
Lucchetti et al.214 
In vivo: Wistar rats A, D, M I.p. injections lead to fast brain absorption (tmax = 30-60 
minutes) and high brain concentrations with a brain-to-
plasma ratio of 24. The t1/2 was determined to be 
approximately 50 minutes. Four metabolites, caused by 
hydroxylation, oxidation, hydrolysis and oxidative 
deamination of cis-4,4′-DMAR were identified in 
plasma and in low concentrations also in the brain.  
Behavioural experiments highlight the rewarding and 
addictive properties of cis-4,4′-DMAR.  
Lucchetti et al.215 
Table 3:  A summary of pharmacokinetic studies on aminorex and its analogs.   
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Behavioral Effects and Dependence Potential 
Stimulus generalization tests conducted with rats revealed that aminorex is similar to 
amphetamine in its effects, albeit slightly less potent151,201. Similar results are available for 4-
methylaminorex153,204. Rexamino, detected as a levamisole metabolite in horses, on the other 
hand, was determined to be inactive in a drug discrimination study in rats trained to 
discriminate (S)-amphetamine from saline, which was consistent with comments made by 
Poos who disclosed that rexamino was devoid of CNS stimulant activity10,63,153. Interestingly, 
derivatives of rexamino have been discovered to be highly potent TAAR1 agonists218. Further 
investigations have revealed that aminorex and 4-methylaminorex substitute for cocaine 
stimuli188. These results have been corroborated in experiments with rhesus monkeys, 
suggesting that aminorex seems to have an abuse liability similar to amphetamine200. Using 
self-administration paradigms in baboons and rhesus monkeys, Mansbach et al. have shown 
that 4-MAR displayed reinforcing effects in primates206. The conditioned place preference test 
has been utilized in rats to assess the rewarding, dopamine-dependent effects of 4-MAR and 
4,4'-DMAR consumption207,215.  
It has been hypothesized that the psychomotoric effects associated with aminorex involved 
interactions with brain receptors or releasing dopamine37. The attribution of effects to 
extracellular dopamine could be confirmed for 4-MAR (for enantiomeric differences see 
above), even though the cited studies did not include measures of extracellular 
norepinephrine, that might also be implicated in the behavioral effects in rats149,150,219,220. 
Batsche and colleagues have considered this option and administered D1 and D2 receptor 
antagonists in conjunction with 4-MAR and noted an attenuation when compared to the 
compound alone152. In addition, serotonin and norepinephrine receptor antagonists proved 
ineffective. These results allude to the possibility that increased locomotor activity in rats 
could be attributed to high extracellular dopamine levels and that it is dose-dependent. It has 
been unveiled for (±)-cis-4,4'-DMAR that the substance also increases locomotor activity215.  
Drug users have described the effects of aminorex derivatives as feeling euphoric, stimulated, 
energized and social and the experience of taking the drugs has been described as being 
similar to both methamphetamine and MDMA144,210,221,222 although further studies are 
warranted to assess similarity to MDMA’s psychopharmacology in humans. With the animal 
model results in mind, one can conclude that aminorex and its derivatives are liable to abuse 
and that they might display dependence potential similar to amphetamine and cocaine.   
 
Adverse Effects and Toxicity  
A trial of aminorex as an anorectic drug revealed that it can cause insomnia, restlessness, 
gastrointestinal, dermatological and cardiovascular side-effects, as well as proteinuria14,189. 
Acute overdoses (between 1-2 mg/kg for humans) can cause symptoms such as seizures,	
hyperreflexia, respiratory depression, mydriasis, tachycardia, hypertension and hyperpnea, 
occurring occur between 15 and 120 mins after consumption189. The fact that aminorex also 
acts as a substrate and releaser at SERT has been linked to pulmonary arterial 
hypertension43,185. Drug users have mentioned hand, muscle twitches, numbness, 
hallucinations, panic attacks, nausea, tachycardia and hyperthermia as unwanted side-effects 
of the consumption of 4-MAR and 4,4'-DMAR144,221. The clinical and autopsy reports of 4,4'-
DMAR patients have described short-term complications such as hyperthermia, seizures, 
hallucinations, agitation, internal bleeding, edema and heart and lung failure133. These 
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symptoms might be explained as the immediate effects of considerable monoamine release, 
caused by this particular drug.135  
Hallucinations caused by high doses of aminorex or derivatives are difficult to measure in 
rodents but have been reported for primates subjected to high-dose self-administration 
regimes206.  
 
Bunker and colleagues have reported that rats receiving 20 mg/kg 4-MAR suffered from 
clonic seizures in the first hour following the treatment and died in the next two to 17 
hours204. Frequent amphetamine-induced seizures can (in rare cases) lead to the development 
of epilepsy and the formation of epileptogenic brain lesions223. It has been shown that seizures 
caused by 4-MAR ingestion can be antagonized by the administration of flunarizine, a 
calcium channel blocker205.   
Zheng et al. have examined the neurotoxic properties of several aminorex analogs in 
comparison to MDMA quantified via long-term depletions in monoamine content 155. They 
concluded that only the trans-(4S,5S)-isomer of 3,4-dimethylaminorex depletes dopaminergic 
and serotonergic neurons with a potency similar to MDMA. It has recently been shown that 
4,4'-DMAR inhibits the vesicular monoamine transporter 2 (VMAT2; SLC18A2) with a 
potency similar to that of MDMA135. Perturbed function of VMAT2 has been associated with 
neurotoxicity224,225. Still, MDMA has been shown to only be neurotoxic when consumed in 
high doses over a long periods of time226–230. As mentioned before, in contrast to other 
amphetamine-type stimulants, 4,4'-DMAR does not interact with TAAR1 and therefore lacks 
the auto-inhibitory pathway that attenuates monoamine release and mediates the 
neuroprotective effects231,232. It has however been shown that many psychoactive compounds 
stimulate human TAAR1 less potently than the receptor’s rodent counterparts184. It is 
currently not confirmed whether aminorex and its derivatives are neurotoxic. The absence of 
the auto-inhibitory pathway and the inhibition of VMAT2 might be relevant factors in the 
determination of the potential neurotoxicity of the compound. Current knowledge would 
suggest that toxic effects might only appear after high dosage consumption over prolonged 
time periods. 
The 5-HT2 receptors (5-HT2A, 5-HT2B and 5-HT2C) are expressed in the endocardium, 
myocardium and the heart valves233,234. It has been shown for MDMA (but also other 
psychostimulants) that binding to the 5-HT2B receptor in particular might possibly be 
associated with valvular heart disease234. On the other hand, these findings could not be 
replicated in other studies235,236. While it has been shown that 4,4'-DMAR binds to the 5-HT2A  
and 5-HT2C receptors135, receptor binding assays for 5-HT2B have not been conducted yet. In 
addition, the interaction of aminorex and other derivatives with the 5-HT2B receptor has not 
yet been subject of investigation. Hence, concerning the long-term cardiotoxicity of aminorex 
and derivatives, at this point in time one can only speculate that, because of their similarity to 
MDMA, a potential interaction with the 5-HT2B receptor might be possibly implicated in 
cardiotoxic effects.  
 
Concluding Remarks 
The historical events linked to aminorex and its derivatives are representative of what has 
occasionally been termed the NPS/”designer drug” phenomenon8,237. The parental drug 
aminorex was originally used as approved medication, yet failed to persist on the market 
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when evidence on adverse side effects accumulated. With the help of existing literature 
describing the properties of a range of closely related drugs, however, new analogs appeared 
on the streets (e.g. 4-MAR). Because of its sympathomimetic effects, a patent claim has been 
filed for the usage of 4-MAR as a nasal decongestant238. Other examples exist where an 
emerging drug that has no history in the scientific (including patent) literature appears for sale 
on the Internet (e.g. 4,4’-DMAR). Today, (4S,5S)-trans-4,4'-DMAR is mentioned in a patent 
as a phospholipase A2 inhibitor and therefore claimed as an anti-inflammatory agent133,239. In 
addition, several isomers of 4,4'-DMAR and related compounds have been patented to be 
utilized in the treatment of CNS disorders133.  
The 4,4’-DMAR case has also illustrated that this drug has escaped the Internet realm 
predominantly relevant to users who had a specific interest in this substance as it 
surreptitiously appeared on the traditional illicit street market where it has been supplied to 
unsuspecting users with tragic consequences. Some Internet suppliers removed the substance 
from their product catalog once information of the adverse effects emerged. Given the 
information available on a range of yet unexplored compounds and the interest of the NPS 
community in the substance group, one might predict further commercial exploitations by 
NPS entrepreneurs and organized crime groups. The gloomy aspect of the NPS phenomenon 
is that information on long-term effects, acute toxicity or pharmacology remains limited, 
combined with the fact that increasingly toxic substances have appeared in recent years5. An 
appreciable body of scientific studies has aimed to elucidate the pharmacodynamic and 
pharmacokinetic properties of NPS. However, considering the rate by which NPS are 
introduced into the markets, the scientific community is constantly trailing and chasing after 
new developments. Furthermore, scientific literature may serve as a rich source for creative 
drug dealers to identify preferable adulterants (such as levamisole) for their products. 
However, the immense amount of data collected on stimulant-type NPS and their structure-
activity relationships may help to identify crucial structural determinants to pave the way for 
the development of improved pharmacotherapies to neuropsychiatric disorders arising from 
imbalances in monoaminergic neurotransmission.  
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Figures 
 
Figure 1. Chemical structures of amphetamine and known aminorex analogs.  
 
 
 
Figure 2. List of aminorex analogs in decreasing order of potency concerning their anorectic 
activity in rats (reduction in consumption of beef broth after oral administration)9,162. In 
comparison, the ED50 value for dextroamphetamine sulfate was 6.8 mg/kg9.  
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Figure 3. Aminorex analogs claimed to have CNS stimulant activity10. The synthesis and 
exploration of effects of 2’-F,4-Methylaminorex has been described by a contributor to an 
online user forum. 
 
 
Figure 4. Synthesis of racemic 4,4’-DMAR134. i) Br2/dichloromethane, 1h at room 
temperature; ii) sodium diformylamide/acetonitrile, 4 h at reflux; iii) HCl/ethanol, overnight 
at room temperature; iv) sodium borohydride/methanol, addition over 1.5 h period; v) 
cyanogen bromide/anhydrous sodium acetate/methanol, 3.5 h on ice, saturated sodium 
carbonate; vi) potassium cyanate/water, 3 h at reflux, 2 M HCl, 2 h at reflux, saturated 
aqueous sodium carbonate.   
 
